(3) Simvastatin, an inhibitor of HMG-CoA reductase (HMGR), is an enzyme in the mevalonate pathway and the rate-limiting enzyme in cholesterol biosynthesis; the reason for inclusion is that statins are reported to have many pleiotropic effects downstream of the mevalonate pathway and to have anti-invasive and anti-inflammatory effects supporting a repurposed anti-cancer use (Matusewicz et al. 2015) (Zaky et al. 2023). Here, HMGA1 is linked to cancer.